Lexaria Bioscien Stock Price, News & Analysis

Lexaria Bioscience (NASDAQ:LEXX) has successfully closed a $4.0 million registered direct offering priced at-the-market under Nasdaq rules. The offering consisted of 2,666,667 shares of common stock at $1.50 per share.

Additionally, the company issued unregistered warrants in a concurrent private placement to purchase up to 2,666,667 shares of common stock with an exercise price of $1.37 per share. These warrants are immediately exercisable and have a five-year expiration term.

H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes, with a focus on supporting their 2026 R&D and business development initiatives.

Lexaria Bioscience (NASDAQ:LEXX), a global drug delivery platform innovator, has announced a $4.0 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,666,667 shares of common stock at $1.50 per share.

Additionally, in a concurrent private placement, Lexaria will issue unregistered warrants to purchase up to 2,666,667 shares with an exercise price of $1.37 per share. The warrants will be immediately exercisable and expire in five years. H.C. Wainwright & Co. serves as the exclusive placement agent, with the offering expected to close around September 29, 2025.

Lexaria Bioscience (Nasdaq:LEXX) has announced positive results from its fluorescently tagged semaglutide (FTS) rodent biodistribution study, demonstrating that its DehydraTECH technology enhances brain delivery of the GLP-1 drug semaglutide.

The study revealed that DehydraTECH-FTS showed higher brain biodistribution compared to Rybelsus® equivalent composition, with the 5mg DehydraTECH-FTS achieving higher brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent. The enhanced brain delivery could potentially improve both safety and efficacy of GLP-1 drugs, particularly in areas related to appetite suppression and nausea reduction.

These findings suggest that Lexaria's technology may enable unique delivery enhancements in brain tissue, potentially supporting improved pharmacodynamic performance of GLP-1 drugs.

Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, announced its participation in the upcoming 27th Annual H.C. Wainwright Global Investment Conference from September 8-10th, 2025.

CEO Richard Christopher will deliver a company presentation, which will be available for remote viewing starting September 5th at 7:00 AM EST. The management team will also be available for one-on-one meetings with investors throughout the conference.

Lexaria Bioscience (NASDAQ:LEXX) has achieved the Last Patient Last Visit (LPLV) milestone in its Phase 1b GLP-1 study in Australia. The study, designated as GLP-1-H24-4, is currently in the laboratory analysis phase where thousands of samples are being processed and analyzed.

The company previously reported positive 8-week interim results showing encouraging safety and tolerability data compared to the Rybelsus® control arm, particularly noting reduced gastrointestinal adverse events. The final report is expected in late 2025.

Lexaria Bioscience (NASDAQ:LEXX) provides an update on the expanding GLP-1 and obesity drug market, highlighting its DehydraTECH technology's potential role. The market is expected to exceed $150 billion by 2030, with 39 new GLP-1 drugs in development from 34 companies.

The company's DehydraTECH platform has demonstrated significant reductions in gastrointestinal adverse events across major GLP-1 drugs, showing improvements ranging from 31% to 100% in various studies. The update also details recent major industry deals, including Novo Nordisk's $2.2 billion collaboration with Septerna, Roche's $5.3 billion rights acquisition from Zealand Pharma, and Regeneron's $1.93 billion licensing deal with Hansoh Pharmaceutical.

Lexaria Bioscience (NASDAQ:LEXX) has reported positive interim 8-week results from its Phase 1b GLP-1-H24-4 study comparing DehydraTECH-enhanced semaglutide and tirzepatide to Rybelsus®. The study revealed that DehydraTECH-semaglutide reduced overall adverse events by 36.5% and gastrointestinal side effects by 43.5% compared to Rybelsus®.

Key findings show that only 79.2% of DehydraTECH-semaglutide patients experienced adverse events, compared to 100% in the Rybelsus® group. For weight loss, DehydraTECH-semaglutide showed a reduction of 1.23% after 8 weeks, while HbA1c levels decreased by 0.14%. The study is expected to complete with final results by the end of 2025.

Lexaria Bioscience (NASDAQ:LEXX) positions its DehydraTECH technology as a potential solution for the GLP-1 industry's biggest challenge: adverse effects. The GLP-1 market is experiencing remarkable growth, with projected revenues increasing from $53.5 billion in 2024 to $70.1 billion in 2025, and expected to reach $156 billion by 2030.

However, 47-64% of GLP-1 users discontinue treatment within 1-2 years, primarily due to gastrointestinal side effects. Notably, 75.7% of patients experience gastrointestinal adverse events with leading GLP-1 drugs. Lexaria's DehydraTECH technology has demonstrated in human clinical testing its ability to reduce side effects in the top three GLP-1 drugs: semaglutide, tirzepatide, and liraglutide.

The company is currently collaborating with a pharmaceutical partner ("PharmaCO") under a material transfer agreement announced in September 2024 to evaluate DehydraTECH compositions.

Lexaria Bioscience (NASDAQ: LEXX) has achieved a significant milestone by securing its 50th worldwide patent, with two new international patents granted. The company received a patent in Australia for epilepsy treatment technology (patent family #24) expiring in 2044, and another in Japan for sublingual nicotine delivery (patent family #20) expiring in 2043. The epilepsy drug market, valued at $9.5B in 2023, is projected to reach $15B by 2032, affecting 50M people in the US. The global retail oral nicotine market, valued at $5.5B in 2023, is expected to grow 26% annually until 2030, with the nicotine pouch market reaching $25.4B by 2030. Altria Ventures Inc., holding 16.67% of Lexaria Nicotine LLC, maintains a non-exclusive license for DehydraTECH with nicotine products.